This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Swine Flu Biotech Bubble Primed to Burst

NEW YORK ( TheStreet) -- As the most fraught influenza season since 1918 moves toward its Northern Hemisphere opening day, one outcome is perhaps more certain than any other: The hysteria surrounding the stocks of certain biotech firms will fade like summer itself.

Ever since swine flu entered the lexicon back in April, a kind of mini-bubble has developed in the shares of companies claiming to have an H1N1 fix, and that bubble seems primed to pop.

More than a few developers of antiviral drugs have seen their stocks explode on little to no evidence that their treatments have any near-term commercial prospects ( see: Biocryst (BCRX - Get Report)). But the case for the bubble's imminent deflation is even clearer among those companies attempting to develop novel influenza vaccines.

Swine Flu Outbreak

Traders, speculators and presumably buy-and-hold investors have piled into these shares. (Early-stage biotech, no matter the specific field, has always been closer to gambling than investing, after all.) Novavax (NVAX - Get Report), a Rockville, Md.-based vaccine specialist, has seen its stock price increase 217% since Jan. 1 -- a relative laggard. Shares of Vical (VICL - Get Report), a San Diego vaccine developer, have gained 256% over the same period, while Inovio (INO - Get Report), also of San Diego, has exploded by 285% and Hemispherix (HEB - Get Report), which has promoted its much-delayed chronic-fatigue treatment as a swine-flu-vaccine booster, has grown by a whopping 478%.

Needless to say, these stocks have outperformed the broader market.

The reason? Press releases by the bale, issued over the last five months touting this or that new study in which some new approach to flu vaccines has shown signs of not only besting the traditional vaccine methods, but of profiting big from any potential swine-flu plague.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
NVS $104.18 1.90%
NVAX $8.28 -0.12%
SNY $51.49 0.23%
VICL $1.00 6.90%
BCRX $10.63 3.30%


DOW 17,984.29 -50.64 -0.28%
S&P 500 2,099.57 -0.83 -0.04%
NASDAQ 5,013.2040 +18.6020 0.37%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs